A secondary analysis of a 12-month randomized trial found 4:3 intermittent fasting improved binge and uncontrolled eating versus daily calorie restriction, with no difference in appetite hormones. PICO summary and expert commentary.
A 6-month randomized sub-analysis found that a multicomponent weight-loss program shifted gut microbiota and linked Faecalibacterium abundance to fat-mass loss, though causation was not established. PICO summary and expert commentary.
A small non-randomised secondary analysis comparing home- and gym-based exercise in older adults with obesity during COVID-19 lockdowns, with PICO summary and expert commentary.
A manufacturer-sponsored secondary analysis found a digital diabetes logbook nearly doubled the odds of reaching HbA1c 6.5% or below at 3 months, with associated real-world glucose reductions. PICO summary and expert commentary.
A 30-participant pilot randomised trial of an 8-week intensive exercise protocol versus diet plus brisk walking in young adults with obesity, with PICO summary and expert commentary.
A post-hoc analysis of the SPRINT trial finds a higher triglyceride-glucose index is associated with greater cardiovascular risk in controlled hypertension, significant only under standard blood pressure treatment. PICO summary and expert commentary.
A small single-blind RCT found that a family-centered empowerment program raised illness acceptance and self-management scores at six weeks in adults with type 2 diabetes. PICO summary and expert commentary.
A one-year randomised controlled trial testing whether pharmacist-led collaborative care improves EQ-5D quality of life and HbA1c versus routine care in adults with diabetes. PICO summary and expert commentary.
A Phase 1 crossover study in healthy Korean volunteers found the enavogliflozin/gemigliptin fixed-dose combination pharmacokinetically equivalent to the separate tablets, with food not altering enavogliflozin exposure. PICO summary and expert commentary.
A 52-week open-label randomized trial found once-weekly semaglutide reduced LDL cholesterol and shifted lipoprotein subfractions toward a less atherogenic profile versus sitagliptin in obese type 2 diabetes. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
